Curaleaf Posts Record Revenue but Faces Margin Pressure

  • Curaleaf reported Q3 2026 revenue of $353M, up 11% YoY, with international revenue growing 28% YoY to $59M.
  • Adjusted gross profit margin declined 186 basis points YoY to 48.7%, while adjusted EBITDA margin fell 56 basis points to 22%.
  • The company expanded its retail footprint to 191 dispensaries, including new openings in Florida and New Jersey.
  • Curaleaf launched an offer to acquire Aurora Cannabis, later enhancing the bid amid Aurora's merger plans with Organigram.
  • Cash position stood at $105M, with $637M in outstanding debt and $50M invested in capital expenditures over nine months.

Curaleaf's Q3 results highlight the tension between revenue growth and margin erosion, a common challenge in the cannabis sector. The company's aggressive retail expansion and international push come as U.S. federal regulations remain a hurdle. The Aurora acquisition attempt underscores Curaleaf's ambition to consolidate the fragmented market, but success hinges on navigating regulatory and competitive obstacles.

Margin Sustainability
Whether Curaleaf can stabilize declining gross margins amid rising operational costs and competitive pressures.
Acquisition Strategy
How Curaleaf's pursuit of Aurora Cannabis will unfold against Organigram's competing merger proposal.
International Expansion
The pace at which Curaleaf can scale its international segment, particularly in Europe, to offset domestic challenges.